Get started
Author

Kyriaki Ioannou

Observed names: K Ioannou, K. Ioannou, KYRIAKI IOANOU
ORCID: 0000-0001-8354-0544
Observed ORCID: 0000-0001-8354-0544
OpenAlex ID: A5080777038
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
2012 · N G Gavalas, M Tsiatas, et al. · British Journal of Cancer · 172
PDF
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy
2012 · Kyriaki Ioannou, Pinelopi Samara, et al. · Cancer Immunology Immunotherapy · 47
Prothymosin Alpha and Immune Responses
2016 · P. Samara, K. Ioannou, et al. · Vitamins and hormones · 42
PDF
New semi-synthetic analogs of oleuropein show improved anticancer activity in vitro and in vivo
2017 · Pinelopi Samara, Nikoleta Christoforidou, et al. · European Journal of Medicinal Chemistry · 37
Prothymosin Alpha: An Alarmin and More...
2017 · Pinelopi Samara, Chrysoula-Evangelia Karachaliou, et al. · Current Medicinal Chemistry · 36
ISO-66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models
2014 · KYRIAKI IOANOU, KAI FAN CHENG, et al. · International Journal of Oncology · 36
PDF
Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo
2009 · Sylvianna Georgaki, Margarita Skopeliti, et al. · Journal of Cellular and Molecular Medicine · 32
PDF
Prothymosin α and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes
2013 · Kyriaki Ioannou, Evelyna Derhovanessian, et al. · BMC Immunology · 24
PDF
Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage?
2009 · Pothitos M. Pitychoutis, Eirini Griva, et al. · The International Journal of Neuropsychopharmacology · 23
PDF
The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro
2012 · Pinelopi Samara, Kyriaki Ioannou, et al. · International Immunopharmacology · 17
The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice
2015 · Gee Jun Tye, Kyriaki Ioannou, et al. · Immunity & Ageing · 12
PDF
Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
2019 · Anastasios I. Birmpilis, Chrysoula-Evangelia Karachaliou, et al. · Cancers · 11
PDF
Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100–109) in sera of mice infected with bacteria
2013 · Pinelopi Samara, Hubert Kalbacher, et al. · Journal of Immunological Methods · 11
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5
Abstract 1733: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo
2021 · Kyriaki Ioannou, Simone Ragusa, et al. · Cancer Research · 3
1078 Prothymosin Alpha and Its Carboxy-terminal Decapeptide ProTalpha(100-109) Induce Th1-type Tumor-specific Immune Responses
2012 · K. Ioannou, E. Derhovanessian, et al. · European Journal of Cancer · 3
Potentiating Local and Abscopal Antitumor Efficacy through Radiation with FAP-CD40 DARPin and Anti-PD1 Therapy
2023 · H.B. Barsoumian, B.E. Nelson, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
PDF
Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary In Silico, In Vitro and In Vivo Investigation
2021 · Anastasios I. Birmpilis, Panagiotis Vitsos, et al. · Current Medicinal Chemistry · 2
1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors
2022 · Hilde De Winter, Elena Fernandez, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Avidity-Engineered CD3 Engaging DARPin ® Targeting Three Tumor Associated Antigens Induce Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety
2021 · Matteo Bianchi, Nina Reschke, et al. · Blood · 1
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
2023 · Carlos Gomez-Roca, Neeltje Steeghs, et al. · Journal for ImmunoTherapy of Cancer
PDF
Phase I trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms
2018 · J. Spicer, V. Kwatra, et al. · Annals of Oncology
In vivo study of the vaccine adjuvants prothymosin alpha and prothymosin alpha(100-109) in melanoma
2017 · P. Samara, K. Ioannou, et al. · Annals of Oncology
Triggering of Toll-like receptors in the elderly. A pilotstudy relevant for vaccination
2017 · Caterina Maria Gambino, Sonya Vasto, et al. · Nova Science Publishers (Nova Science Publishers, Inc.)
PDF
Immune responses induced by the TLR-4 agonist-based adjuvant prothymosin alpha.
2014 · Pinelopi Samara, Kyriaki Ioannou, et al. · Journal of Clinical Oncology
Works count: 27
Citation count: 517
H-index: 11
I10-index: 13
Year
Topic
Type